November 1st, 2018

Allgenesis Biotherapeutics Inc., a Taiwan based specialty pharmaceutical company focused on developing ophthalmologic drugs by both large and small molecules, announced today that IP Australia has issued a Notice of Acceptance for a new Patent covering disintegrin variants Allgenesis has previously licensed from National Cheng Kung University (NCKU).

“Even though Disintegrin is a peptide from snake venom, it has been engineered to be as a safe molecule and having this patent granted in Australia would give us the clearance to use disintegrin variants in our drug design and prevents others from using the same molecules,” said Dr. Madhu Cherukury, Chief Executive Officer of Allgenesis Biotherapeutics Inc. “Disintegrin is a known integrin antagonist that inhibits angiogenesis, inflammation and fibrosis, by incorporating it with other anti-angiogenic factors, we are designing drug candidates that target treatment of various angiogenic diseases, particularly those in ophthalmology.”

NCKU has licensed the global exclusive rights to use sell and manufacture a multi-specific disintegrin variant to Allgenesis. NCKU retains the full ownership of the intellectual property and knowhow related to the disintegrin variant. The newly issued patent provides coverage of the disintegrin variant and its use to treat integrin associated diseases, such as angiogenesis related eye diseases and cancers in Australia up to 2035.

About Allgenesis

Allgenesis is a clinical stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases. AG-73305 is in the CMC stage of the development with IND filing before 1Q2021. AG-86893, a drug for the treatment of Pterygium or better-known as surfer’s eye, is in Phase 2a clinical trial in Australia with FPE in 4Q2018.